{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:34:08Z","timestamp":1793126048175,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107676","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:42:28Z","timestamp":1790232148000},"page":"107676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A multiscale quantitative systems pharmacology platform for early screening of MMAE-based antibody-drug conjugates"],"prefix":"10.1016","volume":"227","author":[{"given":"Qiaoning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3783-8518","authenticated-orcid":false,"given":"Shanshan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107676_bib0001","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.ejps.2026.107676_bib0002","doi-asserted-by":"crossref","DOI":"10.1186\/s41120-018-0026-0","article-title":"Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection","volume":"4","author":"Beaumont","year":"2018","journal-title":"AAPS Open"},{"key":"10.1016\/j.ejps.2026.107676_bib0003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107676_bib0004","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1021\/acsptsci.5c00356","article-title":"Cross-species extrapolation of neonatal fc receptor (FcRn) binding affinity to predict monoclonal antibody pharmacokinetics in humans using physiologically based pharmacokinetic modeling (PBPK): are we there yet?","volume":"8","author":"Benamara","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejps.2026.107676_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2026.107676_bib0006","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrc.2017.92","article-title":"Preclinical mouse solid tumour models: status quo, challenges and perspectives","volume":"17","author":"Gengenbacher","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2026.107676_bib0007","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40262-017-0619-0","article-title":"Antibody-drug conjugates: pharmacokinetic\/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned","volume":"57","author":"Hedrich","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2026.107676_bib0008","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1038\/s41598-020-65860-x","article-title":"Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer antibody-drug conjugates (ADCs)","volume":"10","author":"Hoffmann","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2026.107676_bib0009","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/pharmaceutics17121581","article-title":"Strategic combinations of antibody-drug conjugates from 2023 to 2025: from dual therapies to innovative ADC-based regimens","volume":"17","author":"Jang","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107676_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217535","article-title":"How to design next-generation of antibody-drug conjugates for cancer treatment: lessons from unsuccessful clinical trials","volume":"623","author":"Jian","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2026.107676_bib0011","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s11095-014-1584-z","article-title":"Preclinical pharmacokinetic considerations for the development of antibody drug conjugates","author":"Kamath","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107676_bib0012","first-page":"7","article-title":"QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life","author":"Khera","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2026.107676_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejps.2026.107676_bib0014","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/psp4.12833","article-title":"Development of and insights from systems pharmacology models of antibody-drug conjugates","volume":"11","author":"Lam","year":"2022","journal-title":"CPT. Pharmacometr. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107676_bib0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/00498254.2024.2351044","article-title":"Translational PK\/PD framework for antibody-drug conjugates to inform drug discovery and development","volume":"54","author":"Liao","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2026.107676_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/antib7010010","article-title":"Factors affecting the pharmacology of antibody-drug conjugates","author":"Lucas","year":"2018","journal-title":"Antibodies"},{"key":"10.1016\/j.ejps.2026.107676_bib0017","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1208\/s12248-016-9892-3","article-title":"Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design","author":"Maass","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2026.107676_bib0018","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"Marino","year":"2008","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.ejps.2026.107676_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-019-0391-1","article-title":"An agent-based systems pharmacology model of the antibody-drug conjugate Kadcyla to predict efficacy of different dosing regimens","author":"Menezes","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2026.107676_bib0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s12276-024-01191-5","article-title":"Rebuilding the microenvironment of primary tumors in humans: a focus on stroma","volume":"56","author":"Mun","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejps.2026.107676_bib0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10928-025-10001-y","article-title":"A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor","volume":"52","author":"Ross","year":"2025","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2026.107676_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","author":"Rubahamya","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejps.2026.107676_bib0023","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-023-09884-6","article-title":"Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)","volume":"51","author":"Scheuher","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2026.107676_bib0024","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/pharmaceutics11020098","article-title":"A cell-level systems PK-PD model to characterize In vivo efficacy of ADCs","volume":"11","author":"Singh","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107676_bib0025","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1124\/dmd.117.076414","article-title":"Measurement and mathematical characterization of cell-level pharmacokinetics of antibody-drug conjugates: a case study with Trastuzumab-vc-MMAE","volume":"45","author":"Singh","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2026.107676_bib0026","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/cts.12892","article-title":"Mechanistic modeling of intra-tumor spatial distribution of antibody-drug conjugates: insights into dosing strategies in oncology","volume":"14","author":"Weddell","year":"2021","journal-title":"Clin. Transl. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:55:20Z","timestamp":1793123720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":26,"alternative-id":["S0928098726002502"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107676","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multiscale quantitative systems pharmacology platform for early screening of MMAE-based antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107676"}}